Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Scott Coons
Advertisement
Launch Manager, Commercial Advisory Group, Syneos Health Consulting
Articles by Scott Coons
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
3
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
4
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
5